Pharmacist-Assisted Titration of Rx to Implement Optimal Medical Therapy for Heart Failure (PATRIOT-HF)
Pharmacist-Assisted Titration of Rx to Implement Optimal Medical Therapy for Heart Failure (PATRIOT-HF) (QUE 25-018)
調査の概要
詳細な説明
Heart failure with reduced ejection fraction (HFrEF) affects a large proportion of Veterans and isa leading cause of hospitalization and death. Clinical guidelines recommend four classes of medications (commonly called "quadruple therapy") that improve survival and reduce hospitalizations, yet 42% of Veterans hospitalized with heart failure do not receive all recommended medications at discharge.
This study implements a virtual pharmacist and cardiologist team (hub) that provides digital consultation to hospitalists and primary care providers (spoke) at VA medical centers regarding use of guideline-directed medical therapy (GDMT) during hospitalization and the post-discharge period. The pharmacist/cardiologist team identifies eligible Veterans using a VA hospital-specific dashboard, reviews electronic health records, and places digital consultation notes with individualized medication recommendations, safety surveillance information, and out-of-pocket medication cost data.
The intervention also incorporates identification of Veterans hospitalized in VA-paid community care settings. Veterans hospitalized with heart failure in community hospitals within the preceding 3 months are identified via VA-paid community care claims data, and actionable recommendations are provided through the VA electronic health record or by facsimile to community providers.
Six VA medical centers served by Clinical Resource Hubs in VISNs 4, 16, 17, 19, and 23 are participating. Sites are randomized to one of three implementation waves in a cluster-randomized stepped-wedge design, with implementation occurring every 6 months at two sites per wave. This design allows estimation of intervention effects using both within- and between-site comparisons while controlling for secular trends. A difference-in-differences analytic approach with covariate-constrained randomization is used to estimate causal effects.
The primary effectiveness outcome is change in GDMT optimization score from admission to 14 days after discharge. Secondary effectiveness/safety outcomes include mortality, heart failure readmission, and medication-related adverse events at 90 days. Implementation outcomes are assessed using the RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance) framework and include fidelity to identification of at-risk Veterans, provision of recommendations,, outpatient follow-up rates, and barriers and facilitators to implementation Additional outcomes derived from the RE-AIM framework will also be captured.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Paul L Hess, MD MS
- 電話番号:(720) 857-6889
- メール:paul.hess@va.gov
研究連絡先のバックアップ
- 名前:Lexus L Ujano-De Motta, BS
- 電話番号:(808) 990-3993
- メール:lexus.ujano-demotta@va.gov
研究場所
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045-7211
- Rocky Mountain Regional VA Medical Center, Aurora, CO
-
コンタクト:
- Paul L Hess, MD MS
- 電話番号:720-857-6889
- メール:paul.hess@va.gov
-
主任研究者:
- Paul L Hess, MD MS
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
Admission to a VA medical center or VA-paid community hospital within the preceding 3 months with a primary diagnosis of heart failure
- The primary study cohort will consist of those admitted to a VA medical center, while the secondary study cohort will consist of patients admitted to VA-paid community hospitals
- Left ventricular ejection fraction ≤ 40%
- Not on optimal guideline-directed heart failure medication classes or doses, as assessed in the electronic health record
- Receiving care within one of the 6 participating VA medical centers
Exclusion Criteria:
- Hemodynamic instability
- Receiving comfort care measures alone or enrolled in hospice
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:ヘルスサービス研究
- 割り当て:ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Pharmacist/Cardiologist Virtual Team (Intervention)
VA medical centers randomized to the active intervention period receive digital consultation from a centralized pharmacist and cardiologist virtual team regarding guideline-directed medical therapy for hospitalized Veterans with heart failure and during the post-discharge period.
The intervention includes identification of eligible Veterans, placement of digital consultation notes in the EHR, facilitation of outpatient follow-up, and Veteran education.
|
A centralized pharmacist and cardiologist virtual team (hub) provides protocol-based digital consultation notes to inpatient and outpatient providers(spoke) regarding initiation and intensification of guideline-directed medical therapy (GDMT) for heart failure during hospitalization and the post-discharge transitional care period.
Eligible Veterans are identified via VA dashboards and community care claims data.
Recommendations cover quadruple therapy (beta blockers, ACEI/ARB/ARNI, MRA, SGLT2i) and are tailored to individual clinical presentations.
The pharmacist arranges outpatient follow-up and delivers medication adherence education.
他の名前:
|
|
介入なし:Usual Care (Control Period)
VA medical centers during their pre-implementation (control) period provide usual care for Veterans hospitalized with heart failure without input from the pharmacist/cardiologist virtual team.
In the stepped-wedge design, all sites eventually cross over to the intervention arm.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Guideline-Directed Medical Therapy (GDMT) Optimization Score
時間枠:From hospital admission (baseline) to 14 days after discharge (VA direct care) or 14 days after Veteran eligibility identification (VA community care)
|
The GDMT Optimization Score reflects the proportion of eligible guideline-recommended heart failure medications prescribed relative to the total for which the Veteran is eligible.
Points are assigned as follows - Numerator: ACEI/ARB=1, ARNI=2, evidence-based beta blocker=2, MRA=2, SGLT2i=2, Vericiguat=1, Ivabradine=1, Hydralazine/Nitrates=1. Denominator reflects eligibility for each class.
A higher score indicates greater concordance with guidelines.
|
From hospital admission (baseline) to 14 days after discharge (VA direct care) or 14 days after Veteran eligibility identification (VA community care)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in NIH Heart Failure Collaboratory Score
時間枠:From hospital admission (baseline) to 14 days after discharge (VA direct care) or Veteran eligibility identification (VA community care)
|
A composite GDMT metric assessing the breadth and completeness of guideline-recommended heart failure pharmacotherapy.
|
From hospital admission (baseline) to 14 days after discharge (VA direct care) or Veteran eligibility identification (VA community care)
|
|
All-cause mortality
時間枠:30 days and 90 days after hospital discharge (VA direct care) or Veteran eligibility identification (VA community care)
|
Death from any cause, ascertained from the VA Death Ascertainment File.
|
30 days and 90 days after hospital discharge (VA direct care) or Veteran eligibility identification (VA community care)
|
|
Heart Failure Readmission
時間枠:30 days and 90 days after hospital discharge (VA direct care) or Veteran eligibility identification (VA community care)
|
A claim for inpatient admission with any HF diagnosis on the claim, ascertained from the VA Corporate Data Warehouse and Consolidated Data Set.
|
30 days and 90 days after hospital discharge (VA direct care) or Veteran eligibility identification (VA community care)
|
|
Medication-related adverse outcomes - acute kidney injury
時間枠:90 days after hospital discharge or Veteran eligibility identification
|
Acute kidney injury identified by creatinine levels and ICD diagnostic codes in the VA Corporate Data Warehouse.
|
90 days after hospital discharge or Veteran eligibility identification
|
|
Medication-related adverse outcomes - bradycardia
時間枠:90 after hospital discharge or Veteran eligibility identification
|
Bradycardia identified by vital sign readings and ICD diagnostic codes in the VA Corporate Data Warehouse.
|
90 after hospital discharge or Veteran eligibility identification
|
|
Medication-related adverse outcomes - hyperkalemia
時間枠:90 days after hospital discharge or Veteran eligibility identification
|
Hyperkalemia identified by potassium laboratory values and ICD diagnostic codes in the VA Corporate Data Warehouse.
|
90 days after hospital discharge or Veteran eligibility identification
|
協力者と研究者
捜査官
- 主任研究者:Paul L Hess, MD MS、Rocky Mountain Regional VA Medical Center, Aurora, CO
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- QUX 26-006 (VA Quality Enhancement Research Initiative (QUERI))
- QUE 25-018 (その他の助成金/資金番号:VA Quality Enhancement Research Initiative (QUERI))
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
心不全の臨床試験
-
Novartis Pharmaceuticals完了EC-MPS による治療に関心があり、コア研究の 12 か月の治療期間を無事に完了した患者 (de novo Heart Recipients)